To investigate progression-free survival (PFS) in patients with metastatic colorectal cancer treated with chemotherapy FOLFIRI monotherapy or chemotherapy FOLFIRI combined with Metformin
Aged between 20 and 90 years old
Patients diagnosed with metastatic colorectal cancer who is going to receive FOLFIRI chemotherapy
Female must not be planning to become pregnant or breastfeeding, and not pregnant at any point during treatment. (Contraception is required to participate in this trial)
Those without major physiological diseases (example of major cardiovascular disease is acute myocardial infarction; example of major cerebrovascular disease is acute stroke, malignant hypertension, acute kidney failure, acute liver failure)
Patients other than the above-mentioned main inclusion criteria.
Non-native speakers
Known allergy to metformin or any of its components.
Severe instability in diabetes (ketoacidosis).